drugset / Trial / NCT03257033

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT03257033 ↗

Phase 3 Recruiting 190 enrolled RenovoRx
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Timeline

Start
2018-03-12
Primary completion
2026-06
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Other
Comparator Nab-paclitaxel Small molecule 125 mg/m2 Intravenous